Page 1

Table of Contents ( Mark One ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 10 - K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR Delaware ( State or other jurisdiction of incorporation or organization ) TELA Bio , Inc. ( Exact name of registrant as specified in its charter ) 1 Great Valley Parkway , Suite 24 Malvern , Pennsylvania ( Address of principal executive offices ) For the transition period from to Commission file number : 001-37526 Securities registered pursuant to Section 12 ( b ) of the Act : Title of each class : Common Stock , $ 0.001 par value per share ( 484 ) 320-2930 ( Registrant's telephone number , including area code ) Non - accelerated filer Trading Symbol TELA 45-5320061 ( I.R.S. Employer Identification Number ) 19355 ( Zip Code ) Name of each exchange on which registered : The Nasdaq Global Market Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes > No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes > No Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( §232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit and post such files ) . Yes No Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , smaller reporting company , or an emerging growth company . See the definitions of " large accelerated filer , " “ accelerated filer , " " smaller reporting company , " and " emerging growth company " in Rule 12b - 2 of the Exchange Act . Large accelerated filer Accelerated filer Smaller reporting company Emerging growth company If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C.7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Exchange Act ) . Yes No As of June 30 , 2020 ( the last business day of the registrant's most recently completed second fiscal quarter ) , the aggregate market value of the registrant's common stock held by non - affiliates was approximately $ 103.6 million based on the closing price of the common stock as reported on the NASDAQ Global Market on June 30 , 2020 . As of March 19 , 2021 , the registrant had 14,440,264 shares of Common Stock , $ 0.001 par value per share , outstanding . DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive proxy statement to be filed with the U.S. Securities and Exchange Commission ( the " SEC " ) for TELA Bio's annual meeting of stockholders are incorporated by reference into Part III of this Form 10 - K